Aclaris Therapeutics (ACRS) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed CytomX Therapeutics (CTMX) over the past year, gaining 84.8% versus a loss of 23.4%. Over five years, CTMX leads with a -50.4% price change compared with -79.8% for ACRS. CytomX Therapeutics is the larger company by market cap ($555.6 million vs $500.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | CTMX |
|---|---|---|
| Share price | $3.40 | $2.55 |
| Market cap | $500.48M | $555.64M |
| 1-day change | -8.11% | -0.39% |
| YTD return | +12.96% | -40.14% |
| 1-year return | +84.78% | -23.42% |
| 5-year return | -79.77% | -50.39% |
| EPS (TTM) | $-0.58 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $8.21 |
| 52-week low | $1.74 | $2.48 |
| Distance from 52-week high | -48.48% | -68.94% |
| Average volume | 2.36M | 3.35M |
| Shares outstanding | 147.20M | 217.90M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed CTMX by 108.2 percentage points over the past year.
ACRS vs CTMX FAQ
Which is bigger, Aclaris Therapeutics or CytomX Therapeutics?
CytomX Therapeutics (CTMX) is larger, with a market capitalization of $555.64M compared with $500.48M for Aclaris Therapeutics (ACRS).
Which stock has performed better over the past year, ACRS or CTMX?
ACRS returned +84.78% over the past 12 months, compared with -23.42% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.